Vagus Nerve Stimulation Study Misses Primary Efficacy Endpoint, But QOL Improved

It’s good news/bad news for Boston Scientific’s Vagus Nerve Stimulation plans as a heart failure therapy. While efficacy endpoints suggested no outcome improvement, patients in the treatment group of the sham controlled study reported quality of life improvement.

Boston Scientific Touts Positive 6 Month Data from Lotus™ TAVI Study

New data presented at EuroPCR 2014 in Paris suggests impressive performance at six months for the Lotus™ Valve System, with 79.8 percent of patients showing no paravalvular aortic regurgitation at six months with no cases of severe paravalvular aortic regurgitation in any patient.

Another Back Pain Study Supports Boston’s Precision Spectra™ Spinal Cord Stimulator

New retrospective data presented at the World Institute of Pain (WIP) 7th World Congress demonstrates that Boston Scientific’s Precision Spectra™ Spinal Cord Stimulator (SCS) System provided sustained and highly significant relief of low-back pain six months after implantation.

FDA Green Light for Boston Scientific’s New Defibrillators and Heart Failure Devices

Boston Scientific Corporation has received FDA approval for its latest generation of defibrillators and heart failure devices, including the DYNAGEN™ MINI and INOGEN™ MINI ICDs, as well as the DYNAGEN™ X4 and INOGEN™ X4 CRT-Ds.

FDA and CE Nods for Boston’s Expect™ Slimline (SL) Needle for Fine Needle Aspiration During Endoscopic Ultrasound

Boston Scientific Corporation has received U.S. FDA clearance and CE Mark approval in Europe for the Expect™ Slimline (SL) Needle, which means it is now globally available for Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) procedures.

Boston Scientific’s TAVI Data Stands Up to Big Two

While Edwards Lifesciences and Medtronic slugged it out at ACC 2014 with studies comparing their TAVI (transcatheter aortic valve implantation)offerings, Boston Scientific draws our attention to new data presented at the event that says its own Lotus™ Valve System continued to demonstrate impressive performance at three months.